ABBV Aug 2024 175.000 put
- PR Newswire
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
AbbVie (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. today announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.
- Zacks
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- PR Newswire
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) revealed this year's 20 BOTOX® Cosmetic grant recipients. Each inspiring woman entrepreneur will receive a $25,000 grant, mentorship, and access to community through the BOTOX® Cosmetic grant program in partnership with IFundWomen. The winners were hand-selected by a dedicated panel of experts with support from IFundWomen, aesthetic provider entrepreneurs, and Allergan Aesthetics executive leadership.
